Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled ambroxol hydrochloride solution for lower respiratory tract infection with viscous sputum
CTR20171511Phase 3Active
- Sponsor
- Pharma Stulln
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ambroxol in pulmonary infection, chronic bronchitis (CB), pneumonia, chronic obstructive pulmonary disease (COPD), bronchiectasis, sponsored by Pharma Stulln. Started Feb 2018; status: active.
02
Drugs
ambroxol
03
Conditions
pulmonary infectionchronic bronchitis (CB)pneumoniachronic obstructive pulmonary disease (COPD)bronchiectasis
Beyond the preview
Go deeper on CTR20171511.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20171511.